SCHEDULE: Coastlands Capital Discloses 11.48% Stake in Pasithea Therapeutics

Coastlands Capital LP and affiliated entities have reported beneficial ownership of 11.48% of Pasithea Therapeutics Corp.'s common stock as of April 9, 2026.

Summary

• Coastlands Capital LP, along with its affiliates Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, have jointly filed a Schedule 13G, indicating their beneficial ownership of Pasithea Therapeutics Corp. common stock.
• The filing, dated April 9, 2026, states that these reporting persons collectively beneficially own 3,835,035 shares of common stock.
• This ownership represents 11.48% of the class of securities outstanding.
• The calculation of outstanding shares is based on Pasithea Therapeutics Corp.'s Quarterly Report on Form 10-Q filed on May 15, 2026, which reported 33,414,448 shares outstanding as of May 13, 2026.
• The reporting persons explicitly disclaim membership in a group and beneficial ownership beyond their respective pecuniary interests.
• Pre-funded warrants held by the reporting persons in excess of a 9.99% beneficial ownership limitation are excluded from the reported figures.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data, making it difficult to assess the company's underlying health or future prospects.

Positives

• Significant ownership stake of 11.48% by Coastlands Capital and its affiliates, indicating substantial investment and potential influence.
• The reporting persons are investment advisers and a control person, suggesting a strategic investment rather than a passive one.

Negatives

• The filing does not contain financial performance data or operational updates, making it difficult to assess the company's current health.
• Exclusion of shares issuable from pre-funded warrants above a 9.99% threshold suggests potential for increased ownership, but the exact amount is not specified.

Risks

• Potential for increased ownership by Coastlands Capital beyond the reported 11.48% due to pre-funded warrants, which could impact share price and control dynamics.
• The nature of the investment (passive vs. active) is not fully detailed, leaving open the possibility of future actions that could influence the company's control or strategy.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company. It solely reports on beneficial ownership.

Management Comments

• Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein.
• The filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Coastlands Capital's substantial interest in Pasithea Therapeutics Corp., a biotechnology company, which is typical for investment firms specializing in the sector.

Stakeholder Impact

• Shareholders: The increased stake by a significant investor may signal confidence or lead to future strategic shifts, potentially impacting share price.
• Management: The substantial ownership by Coastlands Capital may lead to increased engagement or influence on corporate strategy and governance decisions.

Next Steps

• Monitor future filings from Coastlands Capital for any changes in ownership or strategic actions.
• Review Pasithea Therapeutics Corp.'s upcoming financial reports and operational updates for insights into company performance.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide sufficient operational or financial information to make a buy or sell recommendation. A 'hold' recommendation is appropriate pending further information on Pasithea Therapeutics Corp.'s performance and Coastlands Capital's intentions.

Keywords

Schedule 13G, Pasithea Therapeutics Corp., Coastlands Capital LP, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Pre-funded Warrants